@article{JTD4061,
author = {Yì-Xiáng J. Wáng and Tiantian Li},
title = {A long way ahead to improve the cost-effectiveness of biomedical research in China},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {3},
year = {2015},
keywords = {},
abstract = {A recent paper by Zhang et al. analyzed the recent hematology literature and compared the output in hematology research from China Mainland with those from US, Europe and Asian countries in recent 10 years from 2004 to 2013. The data showed that although China has made considerable progress in hematology research, the quality of research disproportionally lagged behind (1). This paper reminds us again the major challenges ahead for Chinese biomedical scientists, i.e., to improve the research quality. Zhang et al.’s analysis showed the ranking for cumulative impact factors (IF) of hematology literature was: (I) USA; (II) Germany; (III) UK; (IV) Japan; (V) China; (VI) South Korea. And the ranking for average impact factors was: (I) USA; (II) Germany; (III) UK; (IV) Japan; (V) South Korea; (VI) China. Germany had the highest average citations, while China had the least. The situation of hematology literature output from the six countries in 2009-2013 had little difference from that in 2004-2013. China ranked last in the number of publications in top 25% journals during 2004 to 2013. The result remained surprisingly the same in the period from 2009 to 2013, a period when China’s gross domestic product (GDP) and scientific funding were significantly higher than those from 2004 to 2008. The contribution of Chinese authors to the top 10 hematology journals was also small (2.35%).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/4061}
}